Continuing Avastin into second-line chemotherapy for advanced colorectal cancer when tumors begin to grow larger or new tumors appear (progression) improves both survival time and the time until further progression according to Phase III clinical trial results that will be reported this Sunday morning, June 3, at ASCO 2012 in Chicago
Study results were previewed in an ASCO Press Briefing yesterday.
Overall survival time increased by 19% with Avastin compared to a switch to a new chemotherapy alone. Time until cancer progressed fell 32%. Serious side effects remained similar. Read the rest of this entry »